A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome.
Phase of Trial: Phase II
Latest Information Update: 24 Feb 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Haemangioblastoma; Neuroendocrine tumours; Renal cancer
- Focus Adverse reactions; Biomarker
- 29 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2011 Planned end date changed from Dec 2010 to Dec 2011 as reported by ClinicalTrials.gov.